

Carl Blomqvist

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8636861/carl-blomqvist-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

287
papers

18,586
citations

68
h-index

130
g-index

300
ext. papers

21,736
ext. citations

7.8
avg, IF

5.36
L-index

#	Paper	IF	Citations
287	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. <i>Breast Cancer Research</i> , 2022 , 24, 2	8.3	3
286	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. <i>JAMA Oncology</i> , 2022 ,	13.4	4
285	A graphical LASSO analysis of global quality of life, sub scales of the EORTC QLQ-C30 instrument and depression in early breast cancer.. <i>Scientific Reports</i> , 2022 , 12, 2112	4.9	0
284	Abstract P3-20-02: The association of clinicopathological variables and patient's preference with surgical decision-making for early breast cancer. <i>Cancer Research</i> , 2022 , 82, P3-20-02-P3-20-02	10.1	
283	Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas.. <i>Anticancer Research</i> , 2022 , 42, 1509-1515	2.3	
282	Soft Tissue Sarcoma of Lower Extremity: Functional Outcome and Quality of Life. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6892-6905	3.1	1
281	Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 769-775	4.4	0
280	Risk of primary lung cancer after adjuvant radiotherapy in breast cancer-a large population-based study. <i>Npj Breast Cancer</i> , 2021 , 7, 71	7.8	1
279	Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact. <i>Acta Oncologica</i> , 2021 , 60, 1233-1239	3.2	0
278	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. <i>Scientific Reports</i> , 2021 , 11, 14763	4.9	0
277	Further validation of the Toronto extremity salvage score for lower extremity soft tissue sarcoma based on Finnish patients. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021 , 74, 71-78	1.7	1
276	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021 , 124, 842-854	8.7	2
275	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021 , 12, 1078	17.4	4
274	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021 , 384, 428-439	59.2	143
273	Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients. <i>Anticancer Research</i> , 2021 , 41, 5045-5052	2.3	1
272	Long-term health-related quality of life of breast cancer survivors remains impaired compared to the age-matched general population especially in young women. Results from the prospective controlled BREX exercise study. <i>Breast</i> , 2021 , 59, 110-116	3.6	2
271	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 623-642	4	4

270	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020 , 52, 572-581	36.3	76
269	Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial. <i>Acta Oncologica</i> , 2020 , 59, 660-665	3.2	6
268	SNPs in lncRNA Regions and Breast Cancer Risk. <i>Frontiers in Genetics</i> , 2020 , 11, 550	4.5	6
267	Health-related Quality of Life of Breast Cancer Survivors Attending an Exercise Intervention Study: A Five-year Follow-up. <i>In Vivo</i> , 2020 , 34, 667-674	2.3	6
266	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020 , 44, 442-468	2.6	9
265	Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort. <i>Breast Cancer Research</i> , 2020 , 22, 10	8.3	10
264	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020 , 11, 312	17.4	20
263	Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1. <i>Acta Oncologica</i> , 2020 , 59, 825-832	3.2	2
262	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 423-434	4.4	7
261	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020 , 52, 56-73	36.3	56
260	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020 , 38, 674-685	2.2	133
259	Single centre 30-year experience in treating retroperitoneal liposarcomas. <i>Journal of Surgical Oncology</i> , 2020 , 122, 1163-1172	2.8	0
258	Multidisciplinary Oncovascular Surgery is Safe and Effective in the Treatment of Intra-abdominal and Retroperitoneal Sarcomas: A Retrospective Single Centre Cohort Study and a Comprehensive Literature Review. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020 , 60, 752-763	2.3	9
257	Association of germline variation with the survival of women with pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 44	7.8	3
256	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019 , 9, 12524	4.9	2
255	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431	17.4	45
254	Kaposi sarcoma in Southern Finland (2006-2018). <i>International Journal of Dermatology</i> , 2019 , 58, 1258-1263		2
253	Long-term results of surgical resection of lung metastases from soft tissue sarcoma: A single center experience. <i>Journal of Surgical Oncology</i> , 2019 , 120, 168-175	2.8	9

252	(Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series. <i>Scientific Reports</i> , 2019 , 9, 7304	4.9	3
251	Effectiveness of a 12-month Exercise Intervention on Physical Activity and Quality of Life of Breast Cancer Survivors; Five-year Results of the BREX-study. <i>In Vivo</i> , 2019 , 33, 881-888	2.3	23
250	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019 , 10, 1741	17.4	47
249	The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report. <i>Acta Oncologica</i> , 2019 , 58, 897-900	3.2	1
248	The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors. <i>Radiation Oncology</i> , 2019 , 14, 40	4.2	28
247	Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. <i>International Journal of Cancer</i> , 2019 , 145, 2692-2700	7.5	9
246	Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease. <i>Breast Journal</i> , 2019 , 25, 418-424	1.2	17
245	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019 , 120, 647-657	8.7	28
244	Functional Outcome Measurement in Patients with Lower-Extremity Soft Tissue Sarcoma: A Systematic Literature Review. <i>Annals of Surgical Oncology</i> , 2019 , 26, 4707-4722	3.1	10
243	Reply-Letter to the editor. <i>Breast Journal</i> , 2019 , 25, 1332	1.2	
242	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 38	7.8	12
241	Estrogen receptor beta expression correlates with proliferation in desmoid tumors. <i>Journal of Surgical Oncology</i> , 2019 , 119, 873-879	2.8	3
240	En bloc resection of visceral aorta and right kidney due to aortic sarcoma using temporary extracorporeal bypass grafting. <i>Journal of Vascular Surgery Cases and Innovative Techniques</i> , 2019 , 5, 589-592	1.1	6
239	Prediction and clinical utility of a contralateral breast cancer risk model. <i>Breast Cancer Research</i> , 2019 , 21, 144	8.3	11
238	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019 , 104, 21-34	11	363
237	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019 , 48, 795-806	7.8	52
236	Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 951-956	3.6	7
235	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. <i>Scientific Reports</i> , 2018 , 8, 6574	4.9	19

234	Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy. <i>Familial Cancer</i> , 2018 , 17, 321-331	3	2
233	Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 95-101	4.4	7
232	High cyclin A expression, but not Ki67, is associated with early recurrence in desmoid tumors. <i>Journal of Surgical Oncology</i> , 2018 , 118, 192-198	2.8	4
231	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018 , 50, 968-978	36.3	101
230	Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2018 , 9, 4249-4257	3.3	8
229	Ghrelin expression is associated with a favorable outcome in male breast cancer. <i>Scientific Reports</i> , 2018 , 8, 13586	4.9	4
228	Radiotherapy in desmoid tumors : Treatment response, local control, and analysis of local failures. <i>Strahlentherapie Und Onkologie</i> , 2017 , 193, 269-275	4.3	26
227	High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 667-678	4.4	46
226	Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. <i>Scientific Reports</i> , 2017 , 7, 681	4.9	10
225	High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients. <i>Acta Oncologica</i> , 2017 , 56, 104-106	3.2	6
224	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017 , 551, 92-94	50.4	643
223	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
222	CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. <i>BMC Cancer</i> , 2017 , 17, 620	4.8	21
221	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. <i>Breast Cancer Research</i> , 2017 , 19, 119	8.3	26
220	FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 217-226	4.4	17
219	Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. <i>Nature Communications</i> , 2017 , 8, 1632	17.4	13
218	Inter-observer variation in delineating the coronary arteries as organs at risk. <i>Radiotherapy and Oncology</i> , 2017 , 122, 72-78	5.3	22
217	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. <i>Genetics in Medicine</i> , 2017 , 19, 599-603	6.3	51

216	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017 , 46, 1814-1822	7.8	27
215	Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. <i>International Journal of Breast Cancer</i> , 2017 , 2017, 4351319	2.3	2
214	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017 , 8, 18381-18398	3.3	7
213	- a novel candidate breast cancer susceptibility locus on 6q14.1. <i>Oncotarget</i> , 2017 , 8, 102769-102782	3.3	3
212	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
211	FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome. <i>International Journal of Cancer</i> , 2016 , 139, 2760-2770	7.5	10
210	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. <i>Scientific Reports</i> , 2016 , 6, 36874	4.9	2
209	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	24.4	104
208	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016 , 7, 11375	17.4	64
207	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
206	Radiation dose distribution in coronary arteries in breast cancer radiotherapy. <i>Acta Oncologica</i> , 2016 , 55, 959-63	3.2	27
205	Health-related Quality of Life in Breast Cancer Patients after Adjuvant Treatments. <i>Breast Journal</i> , 2016 , 22, 473-5	1.2	5
204	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016 , 48, 374-86	36.3	93
203	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. <i>British Journal of Cancer</i> , 2016 , 114, 298-304	8.7	5
202	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	65
201	Screening of HELQ in breast and ovarian cancer families. <i>Familial Cancer</i> , 2016 , 15, 19-23	3	4
200	RAD51B in Familial Breast Cancer. <i>PLoS ONE</i> , 2016 , 11, e0153788	3.7	18
199	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016 , 7, 80140-80163	3.3	21

198	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811	5.8	121
197	Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. <i>Breast Cancer Research</i> , 2016 , 18, 98	8.3	26
196	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016 , 18, 64	8.3	25
195	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 117-31	4.4	17
194	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016 , 18, 22	8.3	31
193	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016 , 27, 679-93	2.8	15
192	Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 463-9	4.4	16
191	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. <i>Carcinogenesis</i> , 2015 , 36, 256-71	4.6	12
190	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015 , 47, 373-80	36.3	406
189	Identification of novel genetic markers of breast cancer survival. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	38
188	RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. <i>SpringerPlus</i> , 2015 , 4, 92		17
187	INPP4B and RAD50 have an interactive effect on survival after breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 363-71	4.4	8
186	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , 2015 , 17, 18	8.3	17
185	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015 , 47, 1294-1303	36.3	226
184	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015 , 13, 156	11.4	37
183	The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. <i>BMC Cancer</i> , 2015 , 15, 468	4.8	32
182	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	74
181	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015 , 24, 285-98	5.6	35

180	Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study. <i>Acta Oncologica</i> , 2015 , 54, 538-44	3.2	13
179	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. <i>BMC Cancer</i> , 2015 , 15, 978	4.8	6
178	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015 , 17, 58	8.3	24
177	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. <i>Obstetrical and Gynecological Survey</i> , 2015 , 70, 758-762 ^{2,4}		
176	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015 , 6, 37979-94	3.3	19
175	Prediction of breast cancer risk based on profiling with common genetic variants. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	324
174	Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy. <i>Clinical Cancer Research</i> , 2015 , 21, 4086-4096	12.9	10
173	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. <i>Journal of Pathology: Clinical Research</i> , 2015 , 1, 18-32	5.3	18
172	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015 , 24, 2966-84	5.6	36
171	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015 , 96, 5-20	11	59
170	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015 , 6, 7390-407	3.3	14
169	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. <i>Human Molecular Genetics</i> , 2014 , 23, 1934-46	5.6	28
168	Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 437-41	4.4	1
167	A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 658-69	4	63
166	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014 , 35, 1012-9	4.6	121
165	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 15172-7	11.5	128
164	Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-analysis and collaborative analysis of data for 29,239 cases. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 934-45	4	29
163	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. <i>Nature</i> , 2014 , 514, 92-97	50.4	401

162	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014 , 4, 4999	17.4	87
161	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014 , 23, 6034-46	5.6	11
160	Expression of human chorionic gonadotropin in testicular germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 727-34	2.8	14
159	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014 , 16, R51	8.3	12
158	A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis. <i>PLoS ONE</i> , 2014 , 9, e101488	3.7	24
157	MicroRNA related polymorphisms and breast cancer risk. <i>PLoS ONE</i> , 2014 , 9, e109973	3.7	37
156	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. <i>PLoS Genetics</i> , 2014 , 10, e1004285	6	38
155	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , 2014 , 5, 4051	17.4	13
154	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2014 , 23, 6096-111	5.6	48
153	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014 , 16, 3419	8.3	82
152	Breast cancer with neoaductgenesis: histopathological criteria and its correlation with mammographic and tumour features. <i>International Journal of Breast Cancer</i> , 2014 , 2014, 581706	2.3	11
151	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium 2014 , n/a-n/a		1
150	Quality of life of recently treated patients with breast cancer. <i>Anticancer Research</i> , 2014 , 34, 1201-6	2.3	5
149	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013 , 93, 1046-60	11	80
148	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
147	Identification of genetic markers with synergistic survival effect in cancer. <i>BMC Systems Biology</i> , 2013 , 7 Suppl 1, S2	3.5	1
146	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. <i>American Journal of Human Genetics</i> , 2013 , 92, 489-503	11	167
145	Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. <i>International Journal of Cancer</i> , 2013 , 132, 2044-55	7.5	9

144	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013 , 45, 392-8, 398e1-2	36.3	327
143	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013 , 45, 353-61, 361e1-2	36.3	813
142	Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 79-88	4.4	25
141	Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. <i>Cancer Research</i> , 2013 , 73, 1883-91	10.1	36
140	A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ. <i>International Journal of Breast Cancer</i> , 2013 , 2013, 582134	2.3	17
139	Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. <i>BMC Cancer</i> , 2013 , 13, 512	4.8	49
138	Distribution of coronary artery stenosis after radiation for breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 380-6	2.2	250
137	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012 , 44, 312-8	36.3	237
136	9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1783-91	4	17
135	Effect of image compression and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium. <i>Diagnostic Pathology</i> , 2012 , 7, 29	3	15
134	Hyperglycosylated human chorionic gonadotropin in serum of testicular cancer patients. <i>Clinical Chemistry</i> , 2012 , 58, 1123-9	5.5	20
133	Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. <i>Human Pathology</i> , 2012 , 43, 1363-75	3.7	2
132	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. <i>Human Molecular Genetics</i> , 2012 , 21, 5373-84	5.6	143
131	11q13 is a susceptibility locus for hormone receptor positive breast cancer. <i>Human Mutation</i> , 2012 , 33, 1123-32	4.7	33
130	NQO1 expression correlates inversely with NFB activation in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 955-68	4.4	20
129	19p13.1 is a triple-negative-specific breast cancer susceptibility locus. <i>Cancer Research</i> , 2012 , 72, 1795-803	8.1	93
128	A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. <i>Journal of Medical Genetics</i> , 2012 , 49, 429-32	5.8	35
127	CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4308-16	2.2	134

126	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012 , 21, 3926-39	5.6	75
125	Breast cancer radiotherapy and coronary artery disease: hazards and protection of organs at risk. <i>Breast Cancer Management</i> , 2012 , 1, 13-16	0.7	
124	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , 2012 , 7, e42380	3.7	49
123	Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors. <i>Anticancer Research</i> , 2012 , 32, 3875-84	2.3	51
122	Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2011 , 13, R10	8.3	12
121	Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications. <i>Breast Cancer Research</i> , 2011 , 13, R90	8.3	40
120	Variants on the promoter region of PTEN affect breast cancer progression and patient survival. <i>Breast Cancer Research</i> , 2011 , 13, R130	8.3	34
119	Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 85-95	4.4	14
118	A combined analysis of genome-wide association studies in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 717-27	4.4	85
117	Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. <i>Acta Oncologica</i> , 2011 , 50, 329-37	3.2	10
116	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 250-63	9.7	513
115	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011 , 20, 3289-303	5.6	140
114	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011 , 43, 1210-4	36.3	253
113	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011 , 20, 4693-706	5.6	66
112	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. <i>Journal of Medical Genetics</i> , 2011 , 48, 698-702	5.8	5
111	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. <i>Cancer Research</i> , 2011 , 71, 6240-9	10.1	100
110	RAD51C is a susceptibility gene for ovarian cancer. <i>Human Molecular Genetics</i> , 2011 , 20, 3278-88	5.6	111
109	MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. <i>PLoS ONE</i> , 2011 , 6, e26122	3.7	65

108	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. <i>Nature Structural and Molecular Biology</i> , 2010 , 17, 688-95	17.6	707
107	Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2143-51	4	31
106	Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. <i>PLoS Genetics</i> , 2010 , 6, e1001012	6	36
105	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. <i>PLoS Medicine</i> , 2010 , 7, e1000279	11.6	616
104	Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 650-62	9.7	45
103	A genome-wide association scan on estrogen receptor-negative breast cancer. <i>Breast Cancer Research</i> , 2010 , 12, R93	8.3	32
102	Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families. <i>Breast Cancer Research</i> , 2010 , 12, R50	8.3	15
101	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. <i>Breast Cancer Research</i> , 2010 , 12, R42	8.3	141
100	Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. <i>BMC Cancer</i> , 2010 , 10, 653	4.8	34
99	Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2501-6	4	22
98	Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 230-4	4	44
97	Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1012-8	9.7	90
96	The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer. <i>Acta Oncologica</i> , 2009 , 48, 1137-43	3.2	18
95	The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. <i>Clinical Cancer Research</i> , 2009 , 15, 3214-22	12.9	106
94	The combined status of ATM and p53 link tumor development with therapeutic response. <i>Genes and Development</i> , 2009 , 23, 1895-909	12.6	234
93	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 371-9	4.4	10
92	Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 75-82	4.4	49
91	Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development. <i>The HUGO Journal</i> , 2009 , 3, 31-40		4

90	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. <i>Nature Genetics</i> , 2009 , 41, 585-906.3	393
89	Recruitment of breast cancer survivors into a 12-month supervised exercise intervention is feasible. <i>Contemporary Clinical Trials</i> , 2009 , 30, 457-63	2.3 20
88	Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. <i>Nuclear Medicine and Biology</i> , 2009 , 36, 335-42	2.1 17
87	Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. <i>Breast Cancer Research</i> , 2009 , 11, R89	8.3 31
86	ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer. <i>European Journal of Human Genetics</i> , 2008 , 16, 983-91	5.3 7
85	NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. <i>Nature Genetics</i> , 2008 , 40, 844-53	36.3 163
84	Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. <i>BMC Cancer</i> , 2008 , 8, 6	4.8 26
83	Comprehensive analysis of NuMA variation in breast cancer. <i>BMC Cancer</i> , 2008 , 8, 71	4.8 4
82	Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. <i>Molecular Oncology</i> , 2008 , 2, 296-316	7.9 120
81	Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. <i>Breast Cancer Research</i> , 2008 , 10, R17	8.3 23
80	Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4289-95	2.2 49
79	Free beta-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. <i>Clinical Chemistry</i> , 2008 , 54, 1840-3	5.5 41
78	Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. <i>PLoS Genetics</i> , 2008 , 4, e1000054	6 280
77	Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2008 , 79, 86-93	4.3 177
76	Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. <i>Clinical Cancer Research</i> , 2008 , 14, 1976-83	12.9 21
75	Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. <i>Cancer Research</i> , 2007 , 67, 9584-90	10.1 69
74	Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. <i>Cancer</i> , 2007 , 109, 282-91	6.4 98
73	A common coding variant in CASP8 is associated with breast cancer risk. <i>Nature Genetics</i> , 2007 , 39, 352-836.3	557

72	Mast cells and eosinophils in invasive breast carcinoma. <i>BMC Cancer</i> , 2007 , 7, 165	4.8	57
71	Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. <i>Acta Oncologica</i> , 2007 , 46, 165-71	3.2	8
70	Prognostic role of HuR in hereditary breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6959-63	12.9	86
69	Increased human chorionic gonadotropin due to hypogonadism after treatment of a testicular seminoma. <i>Clinical Chemistry</i> , 2007 , 53, 1560-1	5.5	21
68	Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. <i>Blood</i> , 2007 , 109, 4930-5	2.2	235
67	A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. <i>European Journal of Cancer</i> , 2007 , 43, 1153-60	7.5	19
66	Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2007 , 9, R45	8.3	25
65	Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. <i>Carcinogenesis</i> , 2007 , 28, 1040-5	4.6	16
64	BACH1 Ser919Pro variant and breast cancer risk. <i>BMC Cancer</i> , 2006 , 6, 19	4.8	26
63	ATM variants and cancer risk in breast cancer patients from Southern Finland. <i>BMC Cancer</i> , 2006 , 6, 209	4.8	19
62	Evaluation of RAD50 in familial breast cancer predisposition. <i>International Journal of Cancer</i> , 2006 , 118, 2911-6	7.5	47
61	Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003. <i>Acta Oncologica</i> , 2006 , 45, 736-42	3.2	7
60	TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. <i>Acta Oncologica</i> , 2006 , 45, 590-6	3.2	44
59	Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. <i>Journal of Clinical Oncology</i> , 2006 , 24, 675-80	2.2	137
58	Multicellular tumour spheroid as a model for evaluation of [¹⁸ F]FDG as biomarker for breast cancer treatment monitoring. <i>Cancer Cell International</i> , 2006 , 6, 6	6.4	13
57	Do DNA copy number changes differentiate uterine from non-uterine leiomyosarcomas and predict metastasis?. <i>Modern Pathology</i> , 2006 , 19, 1068-82	9.8	13
56	BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. <i>European Journal of Human Genetics</i> , 2006 , 14, 167-72	5.3	36
55	Does Rituximab Influence the Prognostic Effect of Germinal Centre Phenotype in Diffuse Large B-Cell Lymphoma?.. <i>Blood</i> , 2006 , 108, 2743-2743	2.2	1

54	Increased incidence of stroke in women with breast cancer. <i>European Journal of Cancer</i> , 2005 , 41, 423-9	7.5	67
53	Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. <i>Breast Cancer Research</i> , 2005 , 7, R465-9	8.3	51
52	Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. <i>Breast Cancer Research</i> , 2005 , 7, R93-100	8.3	75
51	Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2005 , 16, 609-15	2.4	11
50	No germline FH mutations in familial breast cancer patients. <i>European Journal of Human Genetics</i> , 2005 , 13, 506-9	5.3	7
49	Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. <i>International Journal of Cancer</i> , 2005 , 113, 575-80	7.5	85
48	Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. <i>Clinical Cancer Research</i> , 2005 , 11, 5098-103	12.9	126
47	A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 1057-63	12.9	78
46	Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. <i>Acta Oncologica</i> , 2004 , 43, 650-6	3.2	165
45	Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel. <i>Acta Oncologica</i> , 2004 , 43, 190-5	3.2	7
44	Genome-wide scanning for linkage in Finnish breast cancer families. <i>European Journal of Human Genetics</i> , 2004 , 12, 98-104	5.3	27
43	Breast cancer on the Internet: the quality of Swedish breast cancer websites. <i>Breast</i> , 2004 , 13, 376-82	3.6	32
42	Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. <i>Breast Cancer Research and Treatment</i> , 2004 , 87, 181-8	4.4	34
41	CHEK2 variant I157T may be associated with increased breast cancer risk. <i>International Journal of Cancer</i> , 2004 , 111, 543-7	7.5	114
40	Autobiographical memories in patients treated for breast cancer. <i>Journal of Psychosomatic Research</i> , 2004 , 57, 363-6	4.1	11
39	Soft-tissue sarcomas of the upper extremity: surgical treatment and outcome. <i>Plastic and Reconstructive Surgery</i> , 2004 , 113, 222-30; discussion 231-2	2.7	31
38	Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial. <i>Acta Oncologica</i> , 2003 , 42, 309-14	3.2	7
37	Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 128-36	4	32

36	Physical performance, toxicity, and quality of life as assessed by the physician and the patient. <i>Acta Oncologica</i> , 2002 , 41, 44-9	3.2	13
35	A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. <i>American Journal of Human Genetics</i> , 2002 , 71, 432-8	11	354
34	The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. <i>Clinical Cancer Research</i> , 2002 , 8, 811-6	12.9	90
33	Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. <i>International Journal of Cancer</i> , 2001 , 93, 368-72	7.5	48
32	Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland). <i>Cancer Causes and Control</i> , 2001 , 12, 739-46	2.8	22
31	Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2001 , 19, 10-7	2.2	278
30	Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. <i>European Journal of Human Genetics</i> , 2000 , 8, 757-63	5.3	64
29	Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. <i>Lancet, The</i> , 2000 , 356, 1384-91	4.0	374
28	Familial Breast Cancer in Southern Finland. <i>Disease Markers</i> , 1999 , 15, 105-105	3.2	78
27	Clinical importance of genomic imbalances in synovial sarcoma evaluated by comparative genomic hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1999 , 115, 39-46		38
26	DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. <i>International Journal of Cancer</i> , 1999 , 84, 114-21	7.5	114
25	Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas. <i>Human Pathology</i> , 1999 , 30, 1247-53	3.7	28
24	Post-mastectomy radiotherapy in pT3N0M0 breast cancer: is it needed?. <i>Radiotherapy and Oncology</i> , 1999 , 52, 213-7	5.3	31
23	Chemotherapy in Ewing's sarcoma. <i>Acta Orthopaedica</i> , 1999 , 70, 69-73		10
22	Treatment-related factors predisposing to chronic pain in patients with breast cancer--a multivariate approach. <i>Acta Oncologica</i> , 1997 , 36, 625-30	3.2	132
21	Long-term prognostic impact of immunohistochemical estrogen receptor determinations compared with biochemical receptor determination in primary breast cancer. <i>Acta Oncologica</i> , 1997 , 36, 530-2	3.2	4
20	Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic hybridization study. <i>Cancer Genetics and Cytogenetics</i> , 1997 , 99, 14-8		59
19	Biweekly dose escalation in curative accelerated hyperfractionation for advanced head and neck cancer: a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 39, 837-40	4	6

18	Complexity of 12q13-22 amplicon in liposarcoma: microsatellite repeat analysis. <i>Genes Chromosomes and Cancer</i> , 1997 , 18, 66-70	5	33
17	Bisphosphonate therapy in metastatic breast cancer. <i>Acta Oncologica</i> , 1996 , 35 Suppl 5, 81-3	3.2	86
16	Cytogenetic study of extraskeletal mesenchymal chondrosarcoma. A case report. <i>Cancer Genetics and Cytogenetics</i> , 1996 , 86, 170-3		10
15	Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1996 , 15, 89-94	5	73
14	Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review. <i>Acta Oncologica</i> , 1996 , 35 Suppl 5, 84-90	3.2	6
13	Results of treatment in testicular nonseminoma. <i>Annals of Medicine</i> , 1996 , 28, 311-4	1.5	
12	Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996 , 19, 232-4	2.7	26
11	A cytogenetic study of malignant fibrous histiocytoma. <i>Cancer Genetics and Cytogenetics</i> , 1995 , 85, 91-6		37
10	Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. <i>Acta Oncologica</i> , 1995 , 34, 629-36	3.2	9
9	Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 263-5	3.5	32
8	The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. <i>European Journal of Surgical Oncology</i> , 1995 , 21, 146-50	3.6	6
7	Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study. <i>European Journal of Cancer</i> , 1993 , 29A, 1677-81	7.5	20
6	FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial. <i>Acta Oncologica</i> , 1992 , 31, 231-6	3.2	10
5	The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. <i>Cancer</i> , 1987 , 60, 2907-12	6.4	47
4	Effect of dichloromethylene diphosphonate (Cl ₂ MDP) on immune function in breast cancer patients with bone metastases. <i>Cancer Immunology, Immunotherapy</i> , 1983 , 15, 159-61	7.4	7
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
2	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes		2
1	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2

